To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients

Inclusion Criteria: * Male or female non-childbearing potential Japanese T2DM patients, 30-75 years. * A body mass index (BMI) of 19 to 27 kg/m2. * Diagnosed Diabetes Mellitus patients treated with diet and exercise or with up to two oral anti-diabetic drugs. Stable glycemic control indicated by no changed treatment within 3 months prior to enrollment. Exclusion Criteria: * Renal dysfunction GFR \< 60 mL/min. * Systolic pressure (SBP) \> 160 mmHg or diastolic pressure (DBP) \> 95 mmHg * Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP. * History of ischemic heart disease, stroke, transient ischemic attack or symptomatic peripheral vascular disease.